依维莫司治疗晚期非小细胞肺癌的临床观察  

Clinical observation of Everolimus in the treatment of advanced non-small cell lung cancer

作　　者：鞠艳芳[1] 焦顺昌[1] 

机构地区：[1]解放军总医院肿瘤内科,北京100853

出　　处：《中国临床实用医学》2014年第4期10-12,共3页China Clinical Practical Medicine

摘　　要：目的：观察依维莫司治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法选取2013年6月至2014年6月解放军总医院收治的晚期 NSCLC 患者18例，给予依维莫司口服或者联合化疗，直至疾病进展或不良反应难以耐受，观察疗效及不良反应。结果18例患者中完全缓解0例，部分缓解0例，稳定10例，进展2例，疾病控制率为55.5%，主要不良反应为口腔炎、咳嗽、腹泻，发生率分别为27.7%、16.6%、16.6%。结论依维莫司口服或者联合化疗可用于治疗晚期 NSCLC，且不良反应可耐受。Objective To evaluate the curative effect and adverse reactions of everolimus in advanced non-small cell lung cancer(NSCLS) patients. Methods From June 2013 to June 2014,18 caces of patients with advanced NSCLC were enrolled in this study in the Chinese PLA General Hospital. Everolimus (5-10 mg) was orally administered daily, some patients received chemotherapy at the same time, 21 days as a cycle. Results There were no patient who got complete or partial remission,10 cases whose condition were stable, 2 cases whose condition were disease progression,the disease control rate was 55.5%. The major adverse reactions of this study were stomatitis, cough and diarrhea , the incidence rate of them were 27.7%, 16.6% and 16.6% respectively. Conclusion Combined everolimus with or without chemotherapy are effective in the treatment of advanced NSCLC, and the adverse reactions are toleranted.

关 键 词：依维莫司 非小细胞肺癌 不良反应 

分 类 号：R[医药卫生]